Consonance Capital Management LP Increased Its Retrophin (RTRX) Stake by $25.61 Million; Cleararc Capital Has Trimmed Its Holding in Amgen Com (AMGN) as Market Value Declined

February 22, 2018 - By Adrian Mccoy

Cleararc Capital Inc decreased its stake in Amgen Inc Com (AMGN) by 6.92% based on its latest 2017Q3 regulatory filing with the SEC. Cleararc Capital Inc sold 1,756 shares as the company’s stock declined 9.68% while stock markets rallied. The institutional investor held 23,620 shares of the biological products (no diagnostic substances) company at the end of 2017Q3, valued at $4.40 million, down from 25,376 at the end of the previous reported quarter. Cleararc Capital Inc who had been investing in Amgen Inc Com for a number of months, seems to be less bullish one the $131.72B market cap company. The stock increased 0.20% or $0.37 during the last trading session, reaching $182.8. About 2.67M shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 5.27% since February 22, 2017 and is uptrending. It has underperformed by 11.43% the S&P500.

Mitchell Blutt increased its stake in Retrophin Inc (RTRX) by 43.76% based on its latest 2017Q3 regulatory filing with the SEC. Consonance Capital Management Lp bought 1.07 million shares as the company’s stock declined 17.61% while stock markets rallied. The hedge fund run by Mitchell Blutt held 3.51 million shares of the health care company at the end of 2017Q3, valued at $87.25M, up from 2.44M at the end of the previous reported quarter. Consonance Capital Management Lp who had been investing in Retrophin Inc for a number of months, seems to be bullish on the $882.04M market cap company. The stock decreased 2.31% or $0.53 during the last trading session, reaching $22.44. About 84,162 shares traded. Retrophin, Inc. (NASDAQ:RTRX) has risen 4.93% since February 22, 2017 and is uptrending. It has underperformed by 11.77% the S&P500.

Since January 5, 2018, it had 0 insider buys, and 2 selling transactions for $44,878 activity. On Friday, January 5 REED ELIZABETH E sold $22,646 worth of Retrophin, Inc. (NASDAQ:RTRX) or 942 shares.

Investors sentiment increased to 1.62 in 2017 Q3. Its up 0.46, from 1.16 in 2017Q2. It increased, as 12 investors sold RTRX shares while 25 reduced holdings. 20 funds opened positions while 40 raised stakes. 40.07 million shares or 1.15% more from 39.61 million shares in 2017Q2 were reported. Credit Suisse Ag reported 55,251 shares or 0% of all its holdings. Voya Inv Mngmt Limited Liability Co reported 0% stake. Los Angeles Mgmt Equity Research stated it has 0% in Retrophin, Inc. (NASDAQ:RTRX). D E Shaw & Inc reported 159,181 shares stake. Jennison Assocs Ltd Limited Liability Company owns 1.40 million shares. 443,818 were reported by Bankshares Of Ny Mellon. 8,154 are held by Trexquant Invest Limited Partnership. Ny State Common Retirement Fund holds 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX) for 40,900 shares. Metropolitan Life Ins Communications New York reported 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX). Bancshares Of Montreal Can owns 119,782 shares. Barclays Public Ltd Com invested in 27,115 shares or 0% of the stock. Invesco Limited holds 1.17 million shares. State Street holds 0% in Retrophin, Inc. (NASDAQ:RTRX) or 1.17M shares. Point72 Asset Mgmt LP has invested 0.05% in Retrophin, Inc. (NASDAQ:RTRX). 125,143 were reported by Morgan Stanley.

Among 4 analysts covering Retrophin (NASDAQ:RTRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Retrophin had 7 analyst reports since August 12, 2015 according to SRatingsIntel. BMO Capital Markets maintained Retrophin, Inc. (NASDAQ:RTRX) rating on Tuesday, November 7. BMO Capital Markets has “Buy” rating and $44.0 target. The stock of Retrophin, Inc. (NASDAQ:RTRX) earned “Mkt Outperform” rating by JMP Securities on Monday, November 2. The firm has “Buy” rating by BMO Capital Markets given on Friday, October 6. The stock of Retrophin, Inc. (NASDAQ:RTRX) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The company was downgraded on Wednesday, August 12 by Zacks.

Consonance Capital Management Lp, which manages about $513.80 million and $904.16M US Long portfolio, decreased its stake in Keryx Biopharmaceuticals Inc (NASDAQ:KERX) by 1.78M shares to 5.23M shares, valued at $37.13 million in 2017Q3, according to the filing. It also reduced its holding in Corcept Therapeutics Inc (NASDAQ:CORT) by 1.92M shares in the quarter, leaving it with 3.88 million shares, and cut its stake in Globus Med Inc (NYSE:GMED).

Among 25 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Therefore 44% are positive. Amgen Inc. had 86 analyst reports since August 3, 2015 according to SRatingsIntel. On Tuesday, November 8 the stock rating was initiated by Mizuho with “Buy”. Mizuho maintained Amgen Inc. (NASDAQ:AMGN) on Monday, February 12 with “Buy” rating. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Neutral” rating by Citigroup on Thursday, February 25. The stock of Amgen Inc. (NASDAQ:AMGN) has “Market Perform” rating given on Friday, February 2 by BMO Capital Markets. Cowen & Co maintained the stock with “Buy” rating in Thursday, February 1 report. As per Thursday, January 18, the company rating was maintained by Piper Jaffray. BMO Capital Markets maintained Amgen Inc. (NASDAQ:AMGN) on Thursday, October 26 with “Market Perform” rating. Morgan Stanley maintained Amgen Inc. (NASDAQ:AMGN) rating on Friday, October 6. Morgan Stanley has “Overweight” rating and $196 target. UBS maintained it with “Neutral” rating and $185 target in Wednesday, July 26 report. The firm has “Buy” rating by Argus Research given on Thursday, July 27.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on April, 25. They expect $3.20 earnings per share, up 1.59% or $0.05 from last year’s $3.15 per share. AMGN’s profit will be $2.31 billion for 14.28 P/E if the $3.20 EPS becomes a reality. After $2.89 actual earnings per share reported by Amgen Inc. for the previous quarter, Wall Street now forecasts 10.73% EPS growth.

Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.16, from 1.15 in 2017Q2. It dived, as 58 investors sold AMGN shares while 511 reduced holdings. 108 funds opened positions while 453 raised stakes. 555.05 million shares or 0.41% less from 557.32 million shares in 2017Q2 were reported. Nottingham Advsrs Inc has invested 0.05% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Mu owns 360 shares. Advisors Limited Liability holds 0.28% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 22,020 shares. Gideon Cap Incorporated owns 2,727 shares. Provident Investment Management invested in 7,650 shares. Copeland Cap Lc accumulated 36,829 shares. Vista Partners reported 1,847 shares stake. Quantitative Inv Limited Liability Corporation, Virginia-based fund reported 177,500 shares. Park Corp Oh reported 0.11% stake. Tokio Marine Asset Mngmt Co holds 0.16% or 5,685 shares in its portfolio. 1,611 are held by Princeton Port Strategies Group Incorporated Limited Liability Company. Kbc Gru Nv stated it has 0.22% in Amgen Inc. (NASDAQ:AMGN). 121,696 were accumulated by Marsico Cap Mgmt Ltd Liability Co. Brick Kyle Associates invested in 1,080 shares. Weaver C Barksdale Assoc Inc accumulated 8,675 shares or 1.8% of the stock.

Cleararc Capital Inc, which manages about $7.05B and $665.83 million US Long portfolio, upped its stake in Valero Energy Corp (NYSE:VLO) by 36,095 shares to 54,468 shares, valued at $4.19M in 2017Q3, according to the filing. It also increased its holding in Nextera Energy Inc (NYSE:NEE) by 12,666 shares in the quarter, for a total of 35,007 shares, and has risen its stake in Amazon Com Inc Com (NASDAQ:AMZN).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>